Contains: 4 x 0.5 mL Single-Dose Prefilled Syringes Push to open PACKAGE/LABEL PRINCIPAL DISPLAY PANEL 0.5 mg Manual Prefilled Syringe PACKAGE LABEL.PRINCIPAL DISPLAY PANEL NDC 0169-1605-14 List 160514 wegovy 0.5 mg (semaglutide) injection 0.5 mg/0.5 mL Use Wegovy 1 time a week For subcutaneous use only Each prefilled syringe delivers 0.5 mg semaglutide Rx only Dispense the enclosed Medication Guide to each patient
Regular check-ins during the first 48 weeks allow for real-time adjustments that prevent dizziness from escalating into treatment discontinuation
Red flag symptoms requiring urgent assessment: Severe, persistent vomiting Inability to tolerate oral intake for more than 24 hours, suggesting possible gastroparesis or other complications Signs of dehydration Decreased urine output, dizziness, dry mucous membranes, or tachycardia Severe abdominal pain Particularly if acute, localized, or associated with fever, which may indicate pancreatitis or other acute abdominal pathology Right upper quadrant pain, fever, or jaundice Suggesting possible gallbladder disease Severe abdominal distension with inability to pass stool or gas Potential bowel obstruction or ileus Hematemesis or melena Suggesting gastrointestinal bleeding Progressive dysphagia Difficulty swallowing that worsens over time Situations requiring routine consultation: Patients should contact their healthcare provider for non-urgent evaluation when experiencing persistent nausea or vomiting lasting beyond 2-3 weeks at a stable dose, as this may indicate inadequate adaptation or the need for dose adjustment
Furthermore, under hypoglycemic conditions, the inhibition of glucagon release does not take place
Each tablet delivers a synergistic blend of vitamin D3 (cholecalciferol) and vitamin K2 (menaquinone-7, MK-7), ensuring optimal absorption and efficacy for adults seeking to maintain strong bones, healthy teeth, and proper calcium metabolism
